NASDAQ · Biotechnology

Amarin Corporation plc (AMRN) Stock

$14.58 +0.80% NASDAQ: AMRN Healthcare

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates.

Valuation

MetricValue
Price$14.58
Market Cap$301.45M
P/E Ratio-9.00
P/B Ratio0.67
P/S Ratio1.40
EPS (TTM)$-1.80
52-Week High$20.90
52-Week Low$12.96
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-7.34%
ROA-5.20%
ROCE-8.01%
Gross Margin52.48%
Operating Margin-17.38%
Net Margin-15.64%
Debt/Equity0.01
Current Ratio3.48

Annual Financials (USD)

Metric20212022202320242025
Revenue$583.0M$369.0M$307.0M$229.0M$214.0M
Operating Profit$11.0M$-106.0M$-57.0M$-92.0M$-14.0M
Net Profit$8.0M$-106.0M$-59.0M$-82.0M$-39.0M
EPS$0.38$-5.20$-3.00$-4.00$-1.80
Op Margin1.8%-28.7%-18.4%-40.1%-6.5%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.1B$886.0M$832.0M$685.0M$671.0M
Total Liabilities$401.0M$291.0M$280.0M$199.0M$211.0M
Cash$219.0M$218.0M$199.0M$121.0M$135.0M
Borrowings$9.0M$10.0M$9.0M$8.0M$12.0M

Latest News

Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year? Zacks · Jul 15, 2026 Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal Zacks · Jul 15, 2026 Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 GlobeNewswire · Jul 15, 2026 CG Oncology Stock Gains 12% in Three Months: What's Driving It? Zacks · Jul 13, 2026 Immunome Stock Up 32% in a Month: Here's What You Should Know Zacks · Jul 10, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-67.0M$-180.0M$7.0M$-31.0M$7.0M
Investing Cash Flow$104.0M$175.0M$-26.0M$-46.0M$9.0M
Financing Cash Flow$-10.0M$-1.0M$-2.0M$-2.0M$-2.0M
Net Cash Flow$32.0M$-5.0M$-18.0M$-78.0M$14.0M
Free Cash Flow$-67.0M$-180.0M$7.0M$-31.0M$7.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.13
EV / EBITDA-34.24
FCF Yield8.46%
Quick Ratio2.46
Interest Coverage0.00
Return 1Y-12.76%
Return 3Y-41.38%
Return 5Y-82.57%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACIU $2.31 +0.22% -4.04 $234.59M 0.00%
ALT $3.03 -1.30% -2.31 $267.42M 0.00%
ANRO $28.67 +0.70% -6.29 $1.01B 0.00%
CLLSCellectis S.A. $2.81 -2.26% -4.14 $282.17M 0.00%
DBVTDBV Technologies S.A. $15.84 +0.83% -3.27 $378.92M 0.00%

About Amarin Corporation plc

Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.

Amarin Corporation plc is headquartered in IE.

Amarin Corporation plc (AMRN) stock trades at $14.58 with a market capitalization of $301.45M. The stock is valued at a price-to-earnings (P/E) ratio of -9.00, price-to-book of 0.67, price-to-sales of 1.40. Over the past 52 weeks the stock has ranged between $12.96 and $20.90, and currently trades 30.2% below its 52-week high.

On profitability, Amarin Corporation plc generates a return on equity (ROE) of -7.34%, return on capital employed of -8.01%, an operating margin of -17.38%, a net profit margin of -15.64%.

Official website: www.amarincorp.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides